blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3474825

EP3474825 - SUSTAINED RELEASE FORMULATION COMPRISING TIZANIDINE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.05.2022
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  18.06.2021
FormerGrant of patent is intended
Status updated on  25.04.2021
FormerExamination is in progress
Status updated on  21.04.2020
FormerRequest for examination was made
Status updated on  29.03.2019
FormerThe international publication has been made
Status updated on  29.12.2017
Formerunknown
Status updated on  04.10.2017
Most recent event   Tooltip27.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 30.10.2024 [2024/44]
Applicant(s)For all designated states
Santa Farma Ilaç Sanayi A.S.
Okmeydani
Boru çiçegi Sok. No:16
Sisli
34382 Istanbul / TR
[2019/18]
Inventor(s)01 / ILHAN, Doga
Santa Farma Ilaç Fabrikasi
Gebkim Kimya Ihtisas Osb Çerkesli Yolu Üzeri Erol
Kiresepi Cad. No:8
Dilovasi, Kocaeli / TR
02 / AKTAS, Tolga
Santa Farma Ilaç Fabrikasi
Gebkim Kimya Ihtisas Osb Çerkesli Yolu Üzeri Erol
Kiresepi Cad. No:8
Dilovasi, Kocaeli / TR
03 / MOLLAOGLU, Fatih
Santa Farma Ilaç Fabrikasi
Gebkim Kimya Ihtisas Osb Çerkesli Yolu Üzeri Erol
Kiresepi Cad. No:8
Dilovasi, Kocaeli / TR
04 / KANIK, Bayram
Santa Farma Ilaç Fabrikasi
Gebkim Kimya Ihtisas Osb
Çerkesli Yolu Üzeri
Erol Kiresepi Cad. No:8
Dilovasi, Kocaeli / TR
05 / ÖNER, Levent
Zirvekent 2. Etap
C2 Blok D:20
Çankaya, Ankara / TR
 [2019/24]
Former [2019/18]01 / ILHAN, Doga
Santa Farma Ilaç Fabrikasi
Gebkim Kimya Ihtisas Osb Çerkesli Yolu Üzeri Erol
Kiresepi Cad. No:8
Dilovasi
Kocaeli / TR
02 / AKTAS, Tolga
Santa Farma Ilaç Fabrikasi
Gebkim Kimya Ihtisas Osb Çerkesli Yolu Üzeri Erol
Kiresepi Cad. No:8
Dilovasi
Kocaeli / TR
03 / MOLLAOGLU, Fatih
Santa Farma Ilaç Fabrikasi
Gebkim Kimya Ihtisas Osb Çerkesli Yolu Üzeri Erol
Kiresepi Cad. No:8
Dilovasi
Kocaeli / TR
04 / KANIK, Bayram
Santa Farma Ilaç Fabrikasi
Sofali Çesme Sok. No: 72-74
Edirnekapi
Istanbul / TR
05 / ÖNER, Levent
Zirvekent 2. Etap
C2 Blok D:20
Çankaya
Ankara / TR
Representative(s)Bulut, Pinar
Farmapatent Limited
GMK Bulvari No: 42/5
Maltepe
06440 Ankara / TR
[2019/18]
Application number, filing date17772138.821.06.2017
[2019/18]
WO2017TR50280
Priority number, dateTR2016000864422.06.2016         Original published format: TR 201608644
[2019/18]
Filing languageTR
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017222488
Date:28.12.2017
Language:EN
[2017/52]
Type: A1 Application with search report 
No.:EP3474825
Date:01.05.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 28.12.2017 takes the place of the publication of the European patent application.
[2019/18]
Type: B1 Patent specification 
No.:EP3474825
Date:21.07.2021
Language:EN
[2021/29]
Search report(s)International search report - published on:EP28.12.2017
ClassificationIPC:A61K9/50, A61K31/433
[2019/18]
CPC:
A61K31/433 (EP); A61K9/5042 (EP); A61K9/5078 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/18]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:RETARD-FORMULIERUNG MIT TIZANIDIN[2019/18]
English:SUSTAINED RELEASE FORMULATION COMPRISING TIZANIDINE[2019/18]
French:FORMULATION À LIBÉRATION PROLONGÉE COMPRENANT DE LA TIZANIDINE[2019/18]
Entry into regional phase15.01.2019National basic fee paid 
15.01.2019Designation fee(s) paid 
15.01.2019Examination fee paid 
Examination procedure13.04.2018Request for preliminary examination filed
International Preliminary Examining Authority: EP
17.01.2019Examination requested  [2019/18]
17.01.2019Date on which the examining division has become responsible
17.04.2019Amendment by applicant (claims and/or description)
24.04.2020Despatch of a communication from the examining division (Time limit: M04)
08.07.2020Reply to a communication from the examining division
26.04.2021Communication of intention to grant the patent
10.05.2021Fee for grant paid
10.05.2021Fee for publishing/printing paid
15.06.2021Receipt of the translation of the claim(s)
Opposition(s)22.04.2022No opposition filed within time limit [2022/26]
Fees paidRenewal fee
15.01.2019Renewal fee patent year 03
15.06.2020Renewal fee patent year 04
10.05.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.06.2017
AL21.07.2021
AT21.07.2021
CY21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
IT21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
MK21.07.2021
MT21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
[2024/44]
Former [2024/23]HU21.06.2017
AL21.07.2021
AT21.07.2021
CY21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
IT21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
MK21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2024/20]HU21.06.2017
AL21.07.2021
AT21.07.2021
CY21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
IT21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2024/18]HU21.06.2017
AL21.07.2021
AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
IT21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2023/08]AL21.07.2021
AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
IT21.07.2021
LT21.07.2021
LV21.07.2021
MC21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/36]AL21.07.2021
AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
IT21.07.2021
LT21.07.2021
LV21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/29]AL21.07.2021
AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/25]AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/24]AT21.07.2021
CZ21.07.2021
DK21.07.2021
EE21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
NL21.07.2021
PL21.07.2021
RO21.07.2021
RS21.07.2021
SE21.07.2021
SK21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/21]AT21.07.2021
DK21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
NL21.07.2021
PL21.07.2021
RS21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/11]AT21.07.2021
ES21.07.2021
FI21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
NL21.07.2021
PL21.07.2021
RS21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
GR22.10.2021
IS21.11.2021
PT22.11.2021
Former [2022/09]AT21.07.2021
ES21.07.2021
FI21.07.2021
LT21.07.2021
NL21.07.2021
RS21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
PT22.11.2021
Former [2022/08]AT21.07.2021
ES21.07.2021
FI21.07.2021
LT21.07.2021
NL21.07.2021
SE21.07.2021
BG21.10.2021
NO21.10.2021
Former [2022/07]AT21.07.2021
LT21.07.2021
NL21.07.2021
NO21.10.2021
Cited inInternational search[A]WO2008003093  (QUESTCOR PHARMACEUTICALS INC [US], et al) [A] 1-17 * paragraph [0007] * * paragraph [0013] ** example 25 *;
 [YD]US2016030399  (PELLEGRINI CARA A [US], et al) [YD] 1-17 * paragraph [0001] * * paragraph [0012] * * examples 1-5 * * tables 1-10 * * claims 36, 38, 39, 45-54 *;
 [YD]  - THRIVENI M ET AL, "Design and evaluation of sustained release multiparticulate system of Tizanidine hydrochloride", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH - IJPSR, SOCIETY OF PHARMACEUTICAL SCIENCES AND RESEARCH, IN, (20130401), vol. 4, no. 4, doi:10.13040/IJPSR.0975-8232.4(4).1614-25, ISSN 0975-8232, page 1614, XP009501370 [YD] 1-17 * the whole document * * abstract * * page 1615, column r, line 18 - page 1616, column l, line 9 * * tables 1,2,7 * * figures 3-6,8-15 *

DOI:   http://dx.doi.org/10.13040/IJPSR.0975-8232.4(4).1614-25
by applicantWO2006102965
 US2014341985
 US2015038539
 US2016030399
    - THRIVENI et al., IJPSR, (20130000), vol. 4, no. 4, pages 1614 - 1625
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.